The US Food and Drug Administration expanded the approval of the anti-PD-1 immunotherapy agent nivolumab to include advanced non-squamous non-small-cell lung cancer.
Cancer Network Staff
A new genetic analysis found five new genetic variants that raise the risk for gliomas. One of the five was associated with a sharply increased risk for glioblastoma.
Adding pertuzumab to first-line therapy for HER2-positive breast cancer has been shown to yield a survival benefit, but a new analysis says adding the drug is not cost effective.
Ponatinib yielded complete cytogenetic responses in most patients with newly diagnosed chronic-phase CML, but the risk of vascular events suggests other agents should first be considered.
Results of a study suggest that durable survival is possible in melanoma patients treated with MAPK inhibitors, and is perhaps similar to the survival observed with ipilimumab.
Whole-exome sequencing found that mutations of the NF1 gene are an important driver mutation in melanoma, and the third most frequently mutated gene.
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.
Alectinib yielded good response rates and was very well tolerated in a phase II trial of patients with advanced, ALK-positive non–small-cell lung cancer.